ArticleOphthalmology science2026
Validation of Ultra-Widefield Autofluorescence Imaging as an Endpoint for Disease Progression in Choroideremia: A Comparative Study.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Promising gene therapy studies in patients with choroideremia (CHM) have failed to meet the primary endpoint of best-corrected visual acuity, but other therapeutic effects in the peripheral fundus may not have been discovered. Ultra-widefield fundus autofluorescence (UWF-FAF) is able to capture peripheral retinal changes as potential structural endpoint. We compared UWF-FAF with conventional FAF in patients with CHM to evaluate its potential as additional imaging modality for future clinical trials. Design: Retrospective cohort study.Subjects: Participants with genetically confirmed CHM and both central 30° and 55° FAF and UWF-FAF imaging available. Methods: Conventional FAF (30° or 55°) and UWF-FAF images obtained on the same day were retrospectively aligned for direct comparison and then analyzed. Two independent graders outlined atrophic areas and preserved retinal pigment epithelium (RPE) islands. Between-modality differences with standard errors, 95% confidence intervals (CIs), and 2-sided Main Outcome Measures: Between-modality differences in area measurements of FAF and UWF-FAF with standard errors, 95% CIs and ICCs. Results: Ninety-six FAF images from 15 patients were included (35 FAF 30°, 20 FAF 55°, and 41 UWF-FAF). Intergrader ICCs ranged from 0.625 to 0.998, indicating good-to-excellent agreement. Within the 30° field, no significant difference was found for the total cohort (0.01; 95% CI, -0.02 to 0.04; Conclusion: In our current study UWF-FAF provided comprehensive atrophy measurements quantitatively comparable to conventional FAF in CHM, supporting its usefulness as a structural clinical trial endpoint for disease progression. Due to significant differences in preserved RPE island measurements the modalities should not be used interchangeably. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.